Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference
June 05 2017 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the
“Company”) (Nasdaq:AVXL), a clinical-stage
biopharmaceutical company developing differentiated therapeutics
for the treatment of neurodegenerative and neurodevelopmental
diseases including Alzheimer’s disease, other central nervous
system (CNS) diseases, pain, and various types of cancer, today
announced that Christopher U. Missling, PhD, President and Chief
Executive Officer, is scheduled to present on Friday, June 9, 2017,
at 10:00 a.m. Eastern Daylight Time, at the Jefferies 2017 Global
Healthcare Conference in New York City.
A live webcast including audio and slides and
subsequent archived replay presentation can be accessed at
http://wsw.com/webcast/jeff105/avxl or via the investor material
page of the Company’s website at
http://www.anavex.com/investors/investor-material/.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain, and various types of cancer. Anavex’s lead drug candidate,
ANAVEX 2-73, recently completed successfully a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. It has also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy and others. The Michael J. Fox Foundation for
Parkinson’s Research has awarded Anavex a research grant to develop
ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund
a preclinical study, which could justify moving ANAVEX 2-73 into a
Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting
sigma-1 and M1 muscarinic receptors, is a promising preclinical
drug candidate demonstrating disease modifications against the
major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available
at www.anavex.com. You can also connect with the company
on Twitter, Facebook and LinkedIn.
To receive ongoing Anavex corporate
communications, please click on the following link to join our
email alert list:
http://www.anavex.com/investors/information-request/.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
203-258-0159
dennisdobsonjr@dobsonmediagroup.com
Social Media:
Bill Douglass
Gotham Communications
646-504-0890
bill@gothamcomm.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024